TOP TEN perturbations for Q9BQ65 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9BQ65
Selected probe(set): 218060_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9BQ65 (218060_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-1.9820623
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-1.8810472
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-1.8271866
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

pediatric meningococcal sepsis study 2 (late) / normal blood sample

Relative Expression (log2-ratio):1.627286
Number of Samples:5 / 3
Experimental pediatric meningococcal sepsis study 2 (late)
Whole blood drawn from children with meningococcal sepsis 24 or 72 hours after admission to the pediatric intensive care unit.
Control normal blood sample
Whole blood drawn from matched control subjects.

G-CSF study 1 / untreated leukocyte sample

Relative Expression (log2-ratio):1.5804167
Number of Samples:5 / 5
Experimental G-CSF study 1
Peripheral blood samples from normal donors for allogenic PBSC transplantation obtained after administration of granulocyte-colony stimulating factor (G-CSF; 10μg/kg/day for five days). Whole blood leukocyte RNA was purified from each sample and used to generate cRNAs.
Control untreated leukocyte sample
Peripheral blood samples from normal donors for allogenic PBSC transplantation obtained before administration of granulocyte-colony stimulating factor (G-CSF). Whole blood leukocyte RNA was purified from each sample and used to generate cRNAs.

tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-1.5236063
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

methylprednisolone; immunoglobulin (IVIG) study 1 / Kawasaki disease study 2 (non-responder)

Relative Expression (log2-ratio):-1.4815722
Number of Samples:4 / 10
Experimental methylprednisolone; immunoglobulin (IVIG) study 1
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after combined treatment with intravenous methylprednisolone (30mg/kg/2h) followed by intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to simple IVIG therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients exhibited good response to the combined therapy. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:, ,
Control Kawasaki disease study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):1.4745502
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)

Relative Expression (log2-ratio):-1.4680061
Number of Samples:4 / 4
Experimental immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

systemic onset JIA study 6 (baseline; placebo) / normal blood sample

Relative Expression (log2-ratio):1.4407244
Number of Samples:22 / 22
Experimental systemic onset JIA study 6 (baseline; placebo)
Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control normal blood sample
Whole blood samples collected from healthy volunteers.